Table 3. Pathway analysis (functional annotation) of the nominally differentially expressed genes (n = 166) between cocaine use disorder patients with low and high anhedonia.
| Category | Term | Count | % | P-value | FDR |
|---|---|---|---|---|---|
| GOTERM_BP_DIRECT | defense response to virus | 13 | 9,6 | 2,1E-9 | 3,2E-6 |
| UP_KEYWORDS | Antiviral defense | 11 | 8,1 | 3,8E-9 | 4,8E-6 |
| UP_KEYWORDS | Immunity | 18 | 13,3 | 2,2E-8 | 2,8E-5 |
| GOTERM_BP_DIRECT | interferon-gamma-mediated signaling pathway | 8 | 5,9 | 6,9E-7 | 1,1E-3 |
| GOTERM_BP_DIRECT | immune response | 15 | 11,1 | 1,7E-6 | 2,6E-3 |
| GOTERM_BP_DIRECT | type I interferon signaling pathway | 7 | 5,2 | 6,0E-6 | 9,3E-3 |
| UP_KEYWORDS | Innate immunity | 11 | 8,1 | 7,3E-6 | 9,1E-3 |
Gene-term enrichment performed on DAVID v. 6.8 (https://david.ncifcrf.gov/). The most relevant (overrepresented) biological terms associated with the list of differentially expressed genes were identified by the DAVID functional annotation chart. Enrichments were calculated with a modified Fisher’s exact test controlled for false discovery rate (FDR).